October 2026 Dermatology Headlines: PASI Data and Label Changes
The October 2026 dermatology roundup pairs week-16 PASI results for prifemilast and ORKA-001 with a revised risankizumab TB label, 37-month data and advocacy.
Topic
Prifemilast
Topic
Prifemilast
Prifemilast Reaches PASI 75 in 57.4% at Week 16 in Phase 3
Randomized phase 3 data showed PASI 75 rates of 51.8% with prifemilast 10 mg and 57.4% with 20 mg at week 16, versus 10.8% with p…